- Home
- NCL vs HSCS Comparison
NCL vs HSCS Comparison
Compare NCL & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCL | HSCS |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.7M | 7.5M |
| IPO Year | 2023 | 2022 |
Fundamental Metrics
Financial Performance| Metric | NCL | HSCS |
|---|---|---|
| Price | $0.34 | $2.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.20 |
| AVG Volume (30 Days) | ★ 18.1M | 67.3K |
| Earning Date | 11-14-2025 | 12-15-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,997,205.00 | $8,669.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.10 | $2.01 |
| 52 Week High | $12.16 | $6.47 |
Technical Indicators
Market Signals| Indicator | NCL | HSCS |
|---|---|---|
| Relative Strength Index (RSI) | 49.01 | 56.95 |
| Support Level | $0.10 | $2.16 |
| Resistance Level | $0.49 | $2.83 |
| Average True Range (ATR) | 0.07 | 0.25 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 60.90 | 81.43 |
Price Performance
Historical ComparisonAbout NCL Northann Corp.
Northann Corp specialized in 3D-printed flooring solutions under its flagship brand, "Benchwick." The company's operations span the full spectrum of additive manufacturing, from sourcing recycled ocean plastics to the final production of intricate flooring designs. It offers an extensive range of proprietary solutions, including Infinite Glass, DSE, TruBevel, and MattMaster, mainly through its sales network in North America and Europe.
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.